Occidental Announces Total Consideration for its Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes and Debentures HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced the consideration payable in respect of its offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) its Zero Coupon Senior Notes due 2036 (the “0.000% 2036 Notes”), 6.125% Senior Notes due 2031 (the “6.125% 2031 Notes”), 6.625% Senior Notes due 2030 (the “6.625% 2030 Notes”), 7.200% Debentures due 2029 (the “7.200% 2029 Debentures”) and 7.950% D...
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human...
Occidental Announces Early Tender Results and Upsize in Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes and Debentures HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced the early tender results, as set forth in the table below, of its offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) its Zero Coupon Senior Notes due 2036 (the “0.000% 2036 Notes”), 6.125% Senior Notes due 2031 (the “6.125% 2031 Notes”), 6.625% Senior Notes due 2030 (the “6.625% 2030 Notes”), 7.200% Debentures due 2029 (the “7.200% 2...
Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarterMore than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025Ended 2025 with $190.7 million in cash and cash equivalents, an increase of $33.2 million from the third quarterRecorded second consecutive quarter of profitability MORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a bi...
Texas Capital Earns Best Bank Award for Middle Market Banking in the U.S. (West) Clients cite strong satisfaction with the firm’s middle market banking DALLAS, March 03, 2026 (GLOBE NEWSWIRE) -- Texas Capital announced today that it has been named as a Best Bank – Likelihood to Recommend for Middle Market Banking in the U.S. (West) by Crisil Coalition Greenwich, recognizing the firm’s approach to serving middle market companies through its client-focused, full-service banking platform. Texas Capital serves small business, middle market and corporate clients across industries and geogra...
Chart Industries Reports Fourth Quarter and Full Year 2025 Financial Results HOUSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Chart Industries, Inc. (NYSE: GTLS) today reported results for the fourth quarter and full year ended December 31, 2025. Full year 2025 compared to full year 2024: Orders of $5.68 billion increased 13.4%; full year 2025 book-to-bill of 1.33Sales of $4.26 billion increased 2.5%; sales increased 4.1% excluding a large lifecycle project and a large aftermarket equipment sale in 2024, which did not repeat in 2025Reported operating income of $358.4 million (8.4% of sales) o...
Moody's Ratings (Moody's) assigned a B1 rating to Matador Resources Company's ("Matador") proposed $750 million senior unsecured notes due 2034. Matador's other ratings, including its Ba3 corporate family rating ("CFR") and stable outlook, remain unchanged. The net proceeds from this debt issuance...
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass Planning underway to initiate Phase 2a multidose portion of WVE-007 INLIGHT clinical trial for obesity in individuals with higher BMI and comorbidities in 1H 2026, as well as additional trials of WVE-007 as an incretin add-on and as post-incretin maintenance in 2...
Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026 MORRISVILLE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that it will report its full year 2025 financial results on Thursday, March 5, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia’s website at . A rebroadcast of the ev...
Photronics Reports First Quarter Fiscal 2026 Results BROOKFIELD, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:PLAB), a worldwide leader in photomask technologies and solutions, today reported financial results for its first quarter of fiscal year 2026 ended February 1, 2026. Commenting on the first quarter performance, Chairman and CEO George Macricostas said, “Photronics delivered strong results in our fiscal first quarter achieving record high-end IC revenue for the second consecutive quarter. We remain on track with our facility expansion plans, which along with continuous proc...
Photronics Reschedules First Quarter 2026 Earnings Conference Call to February 27, 2026 BROOKFIELD, Conn., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PLAB), a worldwide leader in photomask technologies and solutions, today announced that because of inclement weather affecting logistics, its previously scheduled earnings conference call for the first quarter of fiscal 2026, originally set for 8:30 a.m. Eastern time on Wednesday, February 25, 2026, will be rescheduled to 8:30 a.m. Eastern time on Friday, February 27, 2026. The Company will release its financial results for the first quarte...
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET. A live webcast of the ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.